These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 34606672)
1. Values of serum CA125, NSE and 24-hour urine VMA in diagnosis and prediction of treatment of paediatric neuroblastoma. Li J; Liu X; Chen M; Wang J; Wang X Int J Clin Pract; 2021 Dec; 75(12):e14932. PubMed ID: 34606672 [TBL] [Abstract][Full Text] [Related]
2. Clinical value of combined serum CA125, NSE and 24-hour urine VMA for the prediction of recurrence in children with neuroblastoma. Li J; Qi Z; Chen M; Wang J; Liu X Ital J Pediatr; 2023 Aug; 49(1):102. PubMed ID: 37620978 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis. Zhang H; He X; Miao Q; Li L; Song J; Jiang X Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619 [TBL] [Abstract][Full Text] [Related]
4. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Simon T; Hero B; Hunneman DH; Berthold F Eur J Cancer; 2003 Sep; 39(13):1899-903. PubMed ID: 12932669 [TBL] [Abstract][Full Text] [Related]
5. Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma. Berthold F; Hunneman DH; Harms D; Käser H; Zieschang J Eur J Cancer; 1992; 28A(12):1950-4. PubMed ID: 1419287 [TBL] [Abstract][Full Text] [Related]
6. A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma. Sun Q; Chen Y; Jin Q; Yuan X Eur J Pediatr; 2022 Dec; 181(12):4135-4147. PubMed ID: 36149505 [TBL] [Abstract][Full Text] [Related]
7. Analysis of vanillylmandelic acid and homovanillic acid by UPLC-MS/MS in serum for diagnostic testing for neuroblastoma. Sadilkova K; Dugaw K; Benjamin D; Jack RM Clin Chim Acta; 2013 Sep; 424():253-7. PubMed ID: 23830883 [TBL] [Abstract][Full Text] [Related]
8. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: comparison with 24-hour urine collections. Tuchman M; Morris CL; Ramnaraine ML; Bowers LD; Krivit W Pediatrics; 1985 Feb; 75(2):324-8. PubMed ID: 3969335 [TBL] [Abstract][Full Text] [Related]
9. Age dependence and prognostic impact of neuron specific enolase (NSE) in children with neuroblastoma. Berthold F; Engelhardt-Fahrner U; Schneider A; Schumacher R; Zieschang J In Vivo; 1991; 5(3):245-7. PubMed ID: 1893081 [TBL] [Abstract][Full Text] [Related]
10. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Zeltzer PM; Marangos PJ; Evans AE; Schneider SL Cancer; 1986 Mar; 57(6):1230-4. PubMed ID: 3002599 [TBL] [Abstract][Full Text] [Related]
11. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas. Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552 [TBL] [Abstract][Full Text] [Related]
12. Serial determination of serum neuron-specific enolase in patients with neuroblastoma and other pediatric tumors. Tsuchida Y; Honna T; Iwanaka T; Saeki M; Taguchi N; Kaneko T; Koide R; Tsunematsu Y; Shimizu K; Makino S J Pediatr Surg; 1987 May; 22(5):419-24. PubMed ID: 3585664 [TBL] [Abstract][Full Text] [Related]
13. Preanalytical validation and reference values for a mass spectrometric assay of serum vanillylmandelic acid for screening of catecholamine secreting neuroendocrine tumors. Tohmola N; Itkonen O; Turpeinen U; Joenväärä S; Renkonen R; Hämäläinen E Clin Chim Acta; 2015 Jun; 446():206-12. PubMed ID: 25896957 [TBL] [Abstract][Full Text] [Related]
14. Development of a new biochemical test to diagnose and monitor neuroblastoma in Vietnam: homovanillic and vanillylmandelic acid by gas chromatography-mass spectrometry. Tran MT; Baglin J; Tran TT; Hoang KT; Phung LT; Read A; Greaves RF Clin Biochem; 2014 Feb; 47(3):206-15. PubMed ID: 24296288 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma. Di Cataldo A; Dau D; Conte M; Parodi S; De Bernardi B; Giuliano M; Pession A; Viscardi E; Luksch R; Castellano A; Bertuna G; Haupt R; Med Sci Monit; 2009 Jan; 15(1):MT11-8. PubMed ID: 19114976 [TBL] [Abstract][Full Text] [Related]
16. Vanilmandelic acid and homovanillic acid levels in patients with neural crest tumor: 24-hour urine collection versus random sample. Gregianin LJ; McGill AC; Pinheiro CM; Brunetto AL Pediatr Hematol Oncol; 1997; 14(3):259-65. PubMed ID: 9185210 [TBL] [Abstract][Full Text] [Related]
18. Serum neuron-specific enolase as a marker useful for monitoring the effectiveness of therapy in patients with neuroblastoma--as compared with urinary catecholamine metabolites. Hashimoto K; Gotoh Y; Tada K Tohoku J Exp Med; 1986 May; 149(1):25-30. PubMed ID: 3738914 [TBL] [Abstract][Full Text] [Related]
20. Assessment of the diurnal variations in urinary homovanillic and vanillylmandelic acid excretion for the diagnosis and follow-up of patients with neuroblastoma. Tuchman M; Robison LL; Maynard RC; Ramnaraine ML; Krivit W Clin Biochem; 1985 Jun; 18(3):176-9. PubMed ID: 4039636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]